Research Progress on Epidemiological Trend and Risk Factors of Female Breast Cancer

ZHANG Xue; DONG Xiaoping; GUAN Yazhe; REN Meng; GUO Dongli; HE Yutong

doi:10.3971/j.issn.1000-8578.2021.20.0498

Cancer Research on Prevention and Treatment > 2021 > 48(1): 87-92. > DOI: 10.3971/j.issn.1000-8578.2021.20.0498

ZHANG Xue, DONG Xiaoping, GUAN Yazhe, REN Meng, GUO Dongli, HE Yutong. Research Progress on Epidemiological Trend and Risk Factors of Female Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2021, 48(1): 87-92. DOI: 10.3971/j.issn.1000-8578.2021.20.0498

Citation:

PDF (5176 KB)

Research Progress on Epidemiological Trend and Risk Factors of Female Breast Cancer

Institute of Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China

More Information

Corresponding author:
HE Yutong, E-mail: hytong69@yahoo.com
Received Date: May 11, 2020
Revised Date: October 09, 2020
Available Online: January 12, 2024

Graphical Abstract

Abstract

Abstract

Breast cancer is the most common cancer in women all over the world, and it is also the main cause of cancer death in women. In 2018, there were about 2.09 million of new breast cancer cases and 630 thousand of death cases worldwide. The incidence rate of breast cancer varies in different regions of the world, but all of them were on the rise. Although the incidence (36.1/10⁵) and mortality (8.8/10⁵) of female breast cancer in China were relatively low worldwide, the number of female breast cancer cases and deaths in China ranks first in the world. Moreover, the incidence and mortality of female breast cancer in China are increasing in recent year. Breast cancer is a multifactorial disease, mainly including genetic factors, environmental factors and behavioral lifestyle factors, etc. This review aims to explore the epidemiology and related risk factors of breast cancer in the world, so as to understand the prevalence of breast cancer and provide help for the prevention, intervention and early detection of breast cancer.
- Breast cancer,
- Incidence rate,
- Mortality,
- Risk factors,
- Epidemiology

FullText(HTML)

References (50)

References

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. doi: 10.3322/caac.21492
[2]	World Health Organization. Global Cancer Observatory (GCO): Cancer Today[EB/OL].2020-04-01]. http://gco.iarc.fr/today/home.
[3]	Chen WQ, Zheng RS, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer j Clin, 2016, 66(2): 115-132. doi: 10.3322/caac.21338
[4]	Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108. doi: 10.3322/caac.21262
[5]	Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90. doi: 10.3322/caac.20107
[6]	Parkin DM, Bray F, Ferlay J, et al. Global Cancer Statistics, 2002[J]. CA Cancer J Clin, 2005, 55(2): 74-108. doi: 10.3322/canjclin.55.2.74
[7]	Parkin DM. Global cancer statistics in the year 2000[J]. Lancet Oncol, 2001, 2(9): 533-543. doi: 10.1016/S1470-2045(01)00486-7
[8]	Giordano SH. Breast Cancer in Men[J]. N Engl J Med, 2018, 378(24): 2311-2320. doi: 10.1056/NEJMra1707939
[9]	Siegel RL, Miller KD, Jemal A.Cancer Statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1): 7-30. doi: 10.3322/caac.21590
[10]	Australian Government, Australian Institute of Health and Welfare. Breast Screen Australia monitoring report 2019[EB/OL].2020-04-01]. https://www.aihw.gov.au/reports/cancer-screening/breastscreen-australia-monitoring-report-2019/data.
[11]	Siegel R, Naishadham D, Jemal A.Cancer statistics, 2013[J]. CA Cancer J Clin, 2013, 63(1): 11-30. doi: 10.3322/caac.21166
[12]	Li T, Mello-Thoms C, Brennan PC. Descriptive epidemiology of breast cancer in China: incidence, mortality, survival and prevalence[J]. Breast Cancer Res Treat, 2016, 159(3): 395-406. doi: 10.1007/s10549-016-3947-0
[13]	陈万青, 郑荣寿.中国女性乳腺癌发病死亡和生存状况[J].中国肿瘤临床, 2015, 42(13): 668-674. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZL201513010.htm Chen WQ, Zheng RS. Incidence, mortality and survival analysis of breast cancer in China[J]. Zhongguo Zhong Liu Lin Chuang, 2015, 42 (13): 668-674. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZL201513010.htm
[14]	Jia M, Zheng R, Zhang S, et al. Female breast cancer incidence and mortality in 2011, China[J]. J Thorac Dis, 2015, 7(7): 1221-1226.
[15]	Chen W, Zheng R, Zeng H, et al. The incidence and mortality of major cancers in China, 2012[J]. Chin J Cancer, 2016, 35(1): 73. doi: 10.1186/s40880-016-0137-8
[16]	Zuo TT, Zheng RS, Zeng HM, et al. Female breast cancer incidence and mortality in China, 2013[J]. Thorac Cancer, 2017, 8(3): 214-218. doi: 10.1111/1759-7714.12426
[17]	郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志, 2019, 41(1): 19-28. Zheng RS, Sun KX, Zhang SW, et al. Report of cancer epidemiology in China, 2015[J]. Zhonghua Zhong Liu Za Zhi, 2019, 41(1): 19-28.
[18]	李贺, 郑荣寿, 张思维, 等. 2014年中国女性乳腺癌发病与死亡分析[J].中华肿瘤杂志, 2018, 40(3): 166-171. doi: 10.3760/cma.j.issn.0253-3766.2018.03.002 Li H, Zheng RS, Zhang SW, et al. Incidence and mortality of female breast cancer in China, 2014[J]. Zhonghua Zhong Liu Za Zhi, 2018, 40(3): 166-171. doi: 10.3760/cma.j.issn.0253-3766.2018.03.002
[19]	The Centers for Disease Control and Prevention (CDC, The National Cancer Institute (NCI). United States Cancer Statistics: Data Visualizations[EB/OL].2020-05-01]. https://gis.cdc.gov/Cancer/USCS/DataViz.html.
[20]	DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(6): 438-451. doi: 10.3322/caac.21583
[21]	Morey BN, Gee GC, von Ehrenstein OS, et al. Higher Breast Cancer Risk Among Immigrant Asian American Women Than Among US-Born Asian American Women[J]. Prev Chronic Dis, 2019, 16: E20.
[22]	Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013[J]. Ann Oncol, 2013, 24(9): 2206-2223. doi: 10.1093/annonc/mdt303
[23]	Badr LK, Bourdeanu L, Alatrash M, et al. Breast Cancer Risk Factors: a Cross-Cultural Comparison between the West and the East[J]. Asian Pac J Cancer Prev, 2018, 19(8): 2109-2116.
[24]	Sancho-Garnier H, Colonna M. Épidémiologie des cancers du sein[J]. La Presse Médicale, 2019, 48(10): 1076-1084. doi: 10.1016/j.lpm.2019.09.022
[25]	Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet, 2018, 391(10125): 1023-1075.
[26]	Engmann NJ, Golmakani MK, Miglioretti DL, et al. Population-Attributable Risk Proportion of Clinical Risk Factors for Breast Cancer[J]. JAMA Oncol, 2017, 3(9): 1228-1236. doi: 10.1001/jamaoncol.2016.6326
[27]	Meo SA, Suraya F, Jamil B, et al. Association of ABO and Rh blood groups with breast cancer[J]. Saudi J Biol Sci, 2017, 24 (7): 1609-1613. doi: 10.1016/j.sjbs.2017.01.058
[28]	Akin S, Kadri A. Clinical Associations with ABO Blood Group and Rhesus Blood Group Status in Patients with Breast Cancer: A Nationwide Retrospective Study of 3, 944 Breast Cancer Patients in Turkey[J]. Med Sci Monit, 2018, 24: 4698-4703. doi: 10.12659/MSM.909499
[29]	Tan MM, Ho WK, Yoon SY, et al. A case-control study of breast cancer risk factors in 7, 663 women in Malaysia[J]. PLoS One, 2018, 13(9): e0203469. doi: 10.1371/journal.pone.0203469
[30]	Heath AK, Muller DC, van den Brandt PA, et al. Nutrient-wide association study of 92 foods and nutrients and breast cancer risk[J]. Breast Cancer Res, 2020, 22(1): 5. doi: 10.1186/s13058-019-1244-7
[31]	Shetty PJ, Sreedharan J. Breast Cancer and Dietary Fat Intake: A correlational study[J]. Nepal J Epidemiol, 2019, 9(4): 812-816. doi: 10.3126/nje.v9i4.26961
[32]	Xiao YJ, Xia JJ, Li LP, et al. Associations between dietary patterns and the risk of breast cancer: a systematic review and meta-analysis of observational studies[J]. Breast Cancer Res, 2019, 21(1): 16. doi: 10.1186/s13058-019-1096-1
[33]	Houghton SC, Eliassen AH, Zhang SM, et al. Plasma B-vitamins and one-carbon metabolites and the risk of breast cancer in younger women[J]. Breast Cancer Res Treat, 2019, 176(1): 191-203. doi: 10.1007/s10549-019-05223-x
[34]	Meeker JD, Sathyanarayana S, Swan SH. Phthalates and other additives in plastics: human exposure and associated health outcomes[J]. Philos Trans R Soc Lond B Biol Sci, 2009, 364(1526): 2097-2113. doi: 10.1098/rstb.2008.0268
[35]	Ahern TP, Broe A, Lash TL, et al. Phthalate Exposure and Breast Cancer Incidence: A Danish Nationwide Cohort Study[J]. J Clin Oncol, 2019, 37(21): 1800-1809. doi: 10.1200/JCO.18.02202
[36]	Ott SM. Postmenopausal Osteoporosis[J]. N Engl J Med, 2016, 374(21): 2095-2096. doi: 10.1056/NEJMc1602599
[37]	Jha S, Wang Z, Laucis N, et al. Trends in Media Reports, Oral Bisphosphonate Prescriptions, and Hip Fractures 1996-2012: An Ecological Analysis[J]. J Bone Miner Res, 2015, 30(12): 2179-2187. doi: 10.1002/jbmr.2565
[38]	Fournier A, Mesrine S, Gelot A, et al. Use of Bisphosphonates and Risk of Breast Cancer in a French Cohort of Postmenopausal Women[J]. J Clin Oncol, 2017, 35(28): 3230-3239. doi: 10.1200/JCO.2016.71.4337
[39]	Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence[J]. Lancet, 2019, 394(10204): 1159-1168. doi: 10.1016/S0140-6736(19)31709-X
[40]	Rosenberg L, Bethea TN, Viscidi E, et al. Postmenopausal Female Hormone Use and Estrogen Receptor-Positive and -Negative Breast Cancer in African American Women[J]. J Natl Cancer Inst, 2016, 108(4): djv361. doi: 10.1093/jnci/djv361
[41]	Wu JW, Azoulay L, Majdan A, et al. Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes[J]. J Clin Oncol, 2017, 35(32): 3647-3653. doi: 10.1200/JCO.2017.73.4491
[42]	Thakur P, Seam RK, Gupta MK, et al. Breast cancer risk factor evaluation in a Western Himalayan state: A case-control study and comparison with the Western World[J]. South Asian J Cancer, 2017, 6(3): 106-109. doi: 10.4103/sajc.sajc_157_16
[43]	Richmond RC, Anderson EL, Dashti HS, et al. Investigating causal relations between sleep traits and risk of breast cancer in women: mendelian randomisation study[J]. BMJ, 2019, 365: l2327.
[44]	Nichols HB, Schoemaker MJ, Cai J, et al. Breast Cancer Risk After Recent Childbirth: A Pooled Analysis of 15 Prospective Studies[J]. Ann Intern Med, 2019, 170(1): 22-30. doi: 10.7326/M18-1323
[45]	Fortner RT, Sisti J, Chai B, et al. Parity, breastfeeding, and breast cancer risk by hormone receptor status and molecular phenotype: results from the Nurses' Health Studies[J]. Breast Cancer Res, 2019, 21(1): 40. doi: 10.1186/s13058-019-1119-y
[46]	Economopoulou P, Dimitriadis G, Psyrri A. Beyond BRCA: new hereditary breast cancer susceptibility genes[J]. Cancer Treat Rev, 2015, 41(1): 1-8. doi: 10.1016/j.ctrv.2014.10.008
[47]	Park JS, Lee ST, Nam EJ, et al. Variants of cancer susceptibility genes in Korean BRCA1/2 mutation-negative patients with high risk for hereditary breast cancer[J]. BMC Cancer, 2018, 18(1): 83. doi: 10.1186/s12885-017-3940-y
[48]	Chen X, Li Y, Ouyang T, et al. Associations between RAD51D germline mutations and breast cancer risk and survival in BRCA1/2-negative breast cancers[J]. Ann Oncol, 2018, 29(10): 2046-2051. doi: 10.1093/annonc/mdy338
[49]	Reiner AS, Sisti J, John EM, et al. Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study[J]. J Clin Oncol, 2018, 36(15): 1513-1520. doi: 10.1200/JCO.2017.77.3424
[50]	Braithwaite D, Miglioretti DL, Zhu W, et al. Family History and Breast Cancer Risk Among Older Women in the Breast Cancer Surveillance Consortium Cohort[J]. JAMA Intern Med, 2018, 178(4): 494-501. doi: 10.1001/jamainternmed.2017.8642

Cited By

Cited by

Periodical cited type(5)

1.	曹呈尧，金家灿. 乳房全切术联合不同新辅助化疗治疗乳腺癌的疗效及影响因素分析. 浙江创伤外科. 2025(01): 142-146 .
2.	陈春春，唐经纬，孙岩峰，张浩，乔梦祥，郭伟. TCbHP新辅助化疗治疗HER-2阳性乳腺癌的临床疗效及其相关因素研究. 川北医学院学报. 2024(08): 1122-1126 .
3.	王聪. 吡咯替尼联合曲妥珠单抗治疗人表皮生长因子受体2阳性乳腺癌患者的效果. 中国民康医学. 2024(20): 55-58 .
4.	李丹，熊伟. 含注射用紫杉醇(白蛋白结合型)的新辅助TCbHP方案治疗老年乳腺癌的疗效. 临床合理用药. 2024(36): 105-107+111 .
5.	陈世凤，陈怡. 定位针在乳腺癌新辅助化疗后保乳手术中的应用. 中外医药研究. 2024(33): 24-26 .

Other cited types(0)

Get Citation

PDF

XML

Article views (8423) PDF downloads (3131) Cited by(5)

Turn off MathJax

Article Contents

Abstract

References

Research Progress on Epidemiological Trend and Risk Factors of Female Breast Cancer